近年来在临床上广泛应用的化疗药物硼替佐米(Bortezomib)是一种蛋白酶体抑制剂,能够有效阻断NF-κB通路的激活,在多发性骨髓瘤病人的治疗中取得了较好的疗效。
基于1684个网页-相关网页
靶向放疗药物(将放疗射线直接导向癌细胞)。靶向放疗药物主要治疗癌细胞中可使其存活的特定异常物质。硼替佐米(Velcade)和卡非佐米(Kyprolis)是通过手臂静脉注射的两种靶向药物,它们可阻止特定物质在骨髓瘤细胞中分解蛋白质,从而杀死骨髓瘤细胞。
基于376个网页-相关网页
注射用硼替佐米(Bortezomib for Injection)万珂(VELCADE)用于多发性骨髓瘤患者的治疗,此患者在使用本品前至少接受过两种治疗,并在最近一次治疗中病情还在进展。
基于40个网页-相关网页
注射用硼替佐米 Bortezomib for Injection ; Bortezomibfor ; btezomib f injection ; Zh
硼替佐米杂质B Bortezomib impurity ; Bortezomib impurity B -3-Phenyl
硼替佐米杂质A Bortezomib impurity ; Bortezomib impurity A Pyrazine-2-carboxylic acid -amide
硼替佐米杂质N Bortezomib impurity
硼替佐米杂质M Bortezomib impurity
硼替佐米杂质C Bortezomib impurity
硼替佐米异构体杂质 Bortezomib impurity PS619 -3-Phenyl ; Bortezomib impurity PS
硼替佐米杂质D Bortezomib impurity
硼替佐米杂质PS Bortezomib impurity PS
This encouraged us to use a combined treatment with bortezomib and TRAIL for gastric cancer.
这些结果鼓励我们将硼替佐米与TRAIL联合用于胃癌的治疗。
参考来源 - 硼替佐米增强胃癌细胞对TRAIL诱导凋亡的敏感性及机理研究Boriezomib is a kind of proteasome inhibitor,which can inhibit cell growth of multiple myeloma and induce tunor cell apoptosis besides its better effect on the other malignancies of hematological system.
硼替佐米作为一种蛋白酶体抑制剂,能抑制多发性骨髓瘤细胞的生长及诱导肿瘤细胞的凋亡,同时对血液系统其他恶性肿瘤具有显著作用。
参考来源 - 蛋白酶体抑制剂硼替佐米治疗血液恶性肿瘤的研究All adverse events were manageable with roution support. Conclusion:Bortezomid combined with chemotherapy is a new effective therapy in patients with relapse or refractory myeloma which with a high response rate and manageable toxicities.
结论:硼替佐米联合化疗是复发、难治性多发性骨髓瘤的新的治疗方法,是一种可以耐受的、疗效确切的治疗选择。
参考来源 - 硼替佐米联合化疗治疗11例复发、难治性多发性骨髓瘤疗效观察·2,447,543篇论文数据,部分数据来源于NoteExpress
用于治疗难治性抗nmda受体脑炎硼替佐米治疗。
Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis.
该文综述了硼替佐米治疗多发性骨髓瘤的临床应用进展。
Clinical progress on bortezomib in the treatment for multiple myeloma was reviewed.
单用硼替佐米或联合伊立替康对复发或耐药的结直肠癌无效。
Bortezomib alone or in combination with irinotecan was not effective in patients with relapsed or refractory CRC.
应用推荐